Cure My Disease

Don't miss your cure!

 Log in / Sign up

A skin biostimulator aims to reverse sun damage without the peel downtime

NCT ID NCT07722351

Symptom relief Sponsor: Medical University of Silesia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests whether a topical chemical skin biostimulator containing homocysteic acid can improve firmness, wrinkles, texture, and hydration in women aged 39–69 with sun-damaged skin. Twenty-five women receive four treatment sessions two weeks apart, followed by a home-care routine. Researchers measure skin changes before treatment and at 2 and 12 weeks after the series to see if the biostimulator produces lasting improvement without the downtime of traditional chemical peels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a topical chemical skin biostimulator containing ammonium trichloroacetate, homocysteic acid, phytic acid, and citric acid (PRX plus)
What this could lead to
If it works, this could offer a non-invasive option to improve skin firmness, reduce wrinkles, and even out skin tone in aging skin with minimal recovery time.
What could go wrong
This is a small, early study with only 25 women, so results may not apply broadly. The treatment may cause irritation or fail to produce lasting improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Started

Oct 2025

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

39 to 69 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female, Fitzpatrick skin phototype II * Age 39-69 years * Clinical signs of facial photoaging * Some participants had hyperpigmentation (melasma or post-inflammatory hyperpigmentation) Exclusion Criteria: * Pregnancy or breastfeeding * Ongoing hormone therapy * Systemic corticosteroid use within 3 months prior to inclusion * Topical retinoid use within 1 month, or oral retinoid use within 6 months, prior to treatment * Chemical peel procedures within 1 month prior to treatment * Use of arbutin and/or hydroquinone within 3 months prior to treatment * Laser-based treatments within 3 months prior to treatment * Active inflammatory dermatoses * Autoimmune diseases * Renal impairment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperpigmentation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hyperpigmentation hyperpigmentation of the skin Melanosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperpigmentation Skin aging

Contacts and locations

Locations

  • Department of Practical Cosmetology and Skin Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice

    Sosnowiec, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.